RJFSA
TTNP

Raymond James Financial Services Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-61
Closed -$9K – 2909
2020
Q1 		$9K Buy
+61
New +$9.53K ﹤0.01% 2395
2017
Q4 		– Sell
-4
Closed -$27K – 2705
2017
Q3 		$27K Buy
+4
New +$24.8K ﹤0.01% 2494

Other funds holding TTNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Raymond James Financial Services Advisors's TTNP Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Titan Pharmaceuticals (TTNP) in Q2 2020, closing a stake of 61 shares — an estimated $9K sold.

Raymond James Financial Services Advisors first reported a position in TTNP in Q3 2017 and held it in 2 quarters. The position peaked at $27K in Q3 2017. 23 funds tracked by Wall St. Rank hold TTNP as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Titan Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 61 Titan Pharmaceuticals shares in Q2 2020, an estimated $9K.
  • Raymond James Financial Services Advisors first reported a position in Titan Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Titan Pharmaceuticals position peaked at $27K in Q3 2017.
  • 23 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.